Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 EV-to-EBIT is 11.11 as of Jul. 14, 2026, which is 33% below its 10-year median of 16.49. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $51.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 468 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks better than 65.81% on this metric.
The historical rank and industry rank for COSMOS Pharmaceutical's EV-to-EBIT or its related term are showing as below:
CSMYF'
s EV-to-EBIT Range Over the Past 10 Years
Min: 10.63 Med: 16.49 Max: 23.83
Current: 12.12
During the past 13 years, the highest EV-to-EBIT of COSMOS Pharmaceutical was 23.83. The lowest was 10.63. And the median was 16.49.
CSMYF's EV-to-EBIT is ranked better than 65.81% of 468
companies
in the Healthcare Providers & Services industry
Industry Median: 15.795
vs CSMYF: 12.12
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
COSMOS Pharmaceutical's Enterprise Value for the quarter that ended in Feb. 2026 was $3,954 Mil.
COSMOS Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $292 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's EV-to-EBIT falls into.
COSMOS Pharmaceutical's current Enterprise Value is $3,240 Mil.
COSMOS Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $292 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a EV-to-EBIT of 11.11 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on COSMOS Pharmaceutical and its competitors. This is 33% below median its historical median of 16.49. Over the past decade, COSMOS Pharmaceutical's EV-to-EBIT has ranged from 10.63 to 23.83. According to the industry distribution chart, COSMOS Pharmaceutical ranks #160 out of 468 companies in the Healthcare Providers & Services industry, placing it in the top 34.2%.
Is COSMOS Pharmaceutical's EV-to-EBIT too high?
COSMOS Pharmaceutical's current EV-to-EBIT of 11.11 is 33% below median its 10-year median of 16.49. Over the past 10 years, this metric has ranged from a low of 10.63 to a high of 23.83. The Healthcare Providers & Services industry median EV-to-EBIT is 15.80. COSMOS Pharmaceutical's value of 11.11 is 29.7% below this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #160 out of 468 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's EV-to-EBIT compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #160 out of 468 companies for EV-to-EBIT. This puts COSMOS Pharmaceutical in the upper half of its industry. The industry median EV-to-EBIT is 15.80. COSMOS Pharmaceutical's value of 11.11 is 29.7% below this benchmark. Historically, COSMOS Pharmaceutical's own EV-to-EBIT has ranged from 10.63 to 23.83 over the past decade. While the company's 10-year median is 16.49 vs. the industry median of 15.80, COSMOS Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.80, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current EV-to-EBIT of 11.11 is 29.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current EV-to-EBIT is 11.11, which is 33% below median its own 10-year median of 16.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.79, compared to a current price of $37.06 — trading 28.4% below its estimated fair value. The current EV-to-EBIT is 11.11, which is 33% below median its 10-year median of 16.49 and 29.7% below the Healthcare Providers & Services industry median of 15.80. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current EV-to-EBIT is 11.11 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.4% below its estimated GF Value™ of $51.79.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
EV-to-EBIT: 11.11 (33% below median its 10-year median of 16.49)
GF Value™: $51.79 vs. price of $37.06 (28.4% below fair value)
Industry Position: 29.7% below the Healthcare Providers & Services median (#160 of 468)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
